| Bioactivity | Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1)[1]. | ||||||||||||
| Target | CFTR | ||||||||||||
| Invitro | Navocaftor, as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator[1]. | ||||||||||||
| Name | Navocaftor | ||||||||||||
| CAS | 2159103-66-7 | ||||||||||||
| Formula | C15H11F3N4O5S | ||||||||||||
| Molar Mass | 416.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. US 20200377491 Al |
Navocaftor
CAS: 2159103-66-7 F: C15H11F3N4O5S W: 416.33
Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al,
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.